Connection

Co-Authors

This is a "connection" page, showing publications co-authored by ROSEMARIE SCHMANDT and LINGEGOWDA SELANERE MANGALA.
  1. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4454.
    View in: PubMed
    Score: 0.198
  2. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
    View in: PubMed
    Score: 0.085
  3. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2021 04 01; 131(7).
    View in: PubMed
    Score: 0.048
  4. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2018 07 02; 128(7):3199.
    View in: PubMed
    Score: 0.040
  5. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
    View in: PubMed
    Score: 0.028
  6. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
    View in: PubMed
    Score: 0.023
  7. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 2010 Feb; 9(3):176-82.
    View in: PubMed
    Score: 0.022
  8. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
    View in: PubMed
    Score: 0.022
  9. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res. 2009 May 01; 15(9):2971-8.
    View in: PubMed
    Score: 0.021
  10. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.
    View in: PubMed
    Score: 0.018
  11. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.